iBio, Inc. announced that it has entered into a securities purchase agreement for a private investment in public equity to issue 5,287,278 shares of common stock at an issue price of $2.85 per share for the gross proceeds of $?15,068,742.3? and common warrants to purchase up to 5,287,278 shares of common stock warrants. The transaction included participation from ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional and accredited investors. The warrants issued in the offering are exercisable six (6) months upon issuance at an exercise price of $2.64 per share and will expire five years from the date of issuance.

The unregistered shares of common stock, pre-funded warrants and warrants sold in the PIPE financing described above were offered under Section 4(a)(2) of the Securities Act of 1933, as amended (the ?Act?) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and warrants, have not been registered under the Act or applicable state securities laws.